Search results for "Ventricular dysfunction"

showing 10 items of 149 documents

Heart-targeted overexpression of caspase3 in mice increases infarct size and depresses cardiac function

2001

Up-regulation of proapoptotic genes has been reported in heart failure and myocardial infarction. To determine whether caspase genes can affect cardiac function, a transgenic mouse was generated. Cardiac tissue-specific overexpression of the proapoptotic gene Caspase3 was induced by using the rat promoter of α-myosin heavy chain, a model that may represent a unique tool for investigating new molecules and antiapoptotic therapeutic strategies. Cardiac-specific Caspase3 expression induced transient depression of cardiac function and abnormal nuclear and myofibrillar ultrastructural damage. When subjected to myocardial ischemia–reperfusion injury, Caspase3 transgenic mice showed increased inf…

Genetically modified mouseCardiac function curveDNA ComplementaryTransgeneRecombinant Fusion ProteinsMyocardial InfarctionMyocardial IschemiaCaspase 3ApoptosisMice TransgenicMyocardial Reperfusion InjuryDNA FragmentationContractilityMiceVentricular Dysfunction LeftmedicineAnimalsHumansGenetic Predisposition to DiseaseMyocardial infarctionCaspaseMultidisciplinarybiologyCaspase 3MyocardiumBiological Sciencesmedicine.diseasePhenotypeGene Expression RegulationEchocardiographyOrgan SpecificityHeart failureCaspasesCancer researchbiology.proteincardiovascular system
researchProduct

THE NONCOMPACTION OF THE LEFT VENTRICULAR MYOCARDIUM: OUR PEDIATRIC EXPERIENCE

2007

OBJECTIVES: The noncompaction of the left ventricular myocardium is a rare congenital heart disease, characterized by an excessive prominence of trabecular meshwork, spaced out by deep intertrabecular recesses, consequent to the arrest of the normal myocardium embryogenesis. Although there are numerous descriptions, the physiopathological effects of the structural alterations, just like the clinical spectrum and the evolution of the disease, are not totally clarified. In the present study, we have evaluated the natural history of the disease, the familial incidence and the alterations of the systolic and diastolic function. METHODS: We collected a series of 21 young patients who were affect…

Heart Defects CongenitalMalemedicine.medical_specialtygenetic structuresHeart diseaseCardiomyopathyInternal medicineHumansMedicinecardiovascular diseasesNoncompactionChildVentricular dysfunctionUltrasonographybusiness.industryHeart Septal DefectsMyocardiumGeneral Medicinemedicine.diseaseeye diseasesmedicine.anatomical_structureChild Preschoolcardiovascular systemCardiologyLeft ventricular myocardiumFemalesense organsTrabecular meshworkTissue DopplerUltrasonographyCardiology and Cardiovascular Medicinebusiness
researchProduct

Beyond left ventricular ejection fraction there is a right heart that pumps.

2017

Heart Failuremedicine.medical_specialtyEjection fractionVentricular functionbusiness.industryHeartStroke VolumeStroke volume030204 cardiovascular system & hematologymedicine.diseaseVentricular Function Left03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineHeart failureInternal medicineRight heartCardiologyMedicineHumans030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessEuropean journal of heart failure
researchProduct

The role of macrophage colony-stimulating factor in patients with acute myocardial infarction: a pilot study.

2011

We assessed whether macrophage colony-stimulating factor (M-CSF) levels are associated with left ventricular systolic dysfunction (LVSD) in patients with acute myocardial infarction (AMI). We studied 56 patients with AMI (mean age: 67 ± 12 years) and identified those with clinical (Killip class >II) or echocardiographic signs (ejection fraction ≤45%) of LVSD. We evaluated the established cardiovascular risk factors and measured several cardiovascular biomarkers, including M-CSF. Serum M-CSF concentrations (pg/mL) were significantly increased in patients with both clinical and echocardiographic signs of LVSD (460 ± 265 vs 290 ± 210, P = .0103 and 493 ± 299 vs 287 ± 174, P = .0028, respec…

Macrophage colony-stimulating factorMalemedicine.medical_specialtymacrophage colony-stimulating factor myocardial infarction heart failureMyocardial InfarctionPilot ProjectsLogistic regressionVentricular Dysfunction LeftPredictive Value of TestsInternal medicineMedicineHumansMyocardial infarctionKillip classAgedEjection fractionbusiness.industryMacrophage Colony-Stimulating FactorOdds ratiomedicine.diseaseConfidence intervalPredictive value of testsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersAngiology
researchProduct

Myocardial maladaptation to pressure overload in CB2 receptor-deficient mice

2019

Abstract Background Adaptation to aortic valve stenosis leads to myocardial hypertrophy, which has been associated with inflammation, fibrosis and activation of the endocannabinoid system. Since the endocannabinoid system and the CB2 receptor provide cardioprotection and modulate immune response in experimental ischemia, we investigated the role of CB2 in a mouse model of cardiac pressure overload. Methods Transverse aortic constriction was performed in CB2 receptor-deficient (Cnr2−/−) mice and their wild-type littermates (Cnr2+/+). After echocardiography and Millar left heart catheter hemodynamic evaluation hearts were processed for histological, cellular and molecular analyses. Results Th…

Male0301 basic medicinemedicine.medical_specialtyGenotypeFluorescent Antibody TechniqueBlood PressureCardiomegalyInflammation030204 cardiovascular system & hematologyProinflammatory cytokineReceptor Cannabinoid CB2Mice03 medical and health sciences0302 clinical medicineImmune systemFibrosisInternal medicineVentricular DysfunctionmedicineAnimalsMyocytes CardiacMolecular BiologyMice KnockoutPressure overloadCardioprotectionVentricular RemodelingChemistryMyocardiumHemodynamicsmedicine.diseaseImmunohistochemistryEndocannabinoid systemDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyFemaleInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular MedicineMyofibroblastBiomarkersEndocannabinoidsJournal of Molecular and Cellular Cardiology
researchProduct

The risk factor age in normotensive patients with pulmonary embolism: Effectiveness of age in predicting submassive pulmonary embolism, cardiac injur…

2015

Abstract Introduction Right ventricular dysfunction (RVD), submassive pulmonary embolism (PE), elevated systolic pulmonary artery pressure (sPAP), elevated cardiac troponin I (cTnI) and old age are well-known risk factors for poor outcome in acute normotensive PE. The aim of this analysis was to calculate age cut-off values to predict submassive PE, cardiac injury, RVD and elevated sPAP in normotensive PE patients. Methods Retrospective analysis of clinical, laboratory, radiological and echocardiographic data of normotensive PE patients (2006–2011) was performed. Receiver operating characteristic (ROC) curves and Youden indexes were used to test the effectiveness of using patients' ages at …

MaleAgingmedicine.medical_specialtyCardiac troponinVentricular Dysfunction RightBlood PressureBiochemistryRisk AssessmentEndocrinologyRisk FactorsInternal medicinemedicine.arteryGermanyTroponin IGeneticsmedicineHumansPulmonary Wedge PressureRisk factorMolecular BiologyAgedRetrospective StudiesReceiver operating characteristicbusiness.industryTroponin IAge FactorsCell Biologymedicine.diseasePrognosisThrombosisRight ventricular dysfunctionPulmonary embolismROC CurveEchocardiographyPulmonary arteryAcute DiseaseCardiologyFemalebusinessPulmonary EmbolismExperimental gerontology
researchProduct

Renal function as a cofactor for risk stratification and short-term outcome in acute pulmonary embolism

2017

Abstract Background In addition to right ventricular dysfunction (RVD) and myocardial injury, impaired renal function is connected with poorer prognosis in pulmonary embolism (PE). We aimed to investigate renal function as a cofactor for risk stratification in PE. Methods Data from 182 patients with PE, treated between May 2006 and June 2011, were analysed retrospectively. PE patients with elevated creatinine were compared with those with normal values. Logistic regression models were calculated to investigate associations between creatinine and myocardial necrosis, RVD and in-hospital death. Prognostic performance of creatinine for prediction of myocardial necrosis and RVD were computed. R…

MaleAgingmedicine.medical_specialtyVentricular Dysfunction RightRenal function030204 cardiovascular system & hematologyKidneyLogistic regressionRisk AssessmentBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGermanyInternal medicinemedicine.arteryTroponin IGeneticsmedicineHumans030212 general & internal medicineMolecular BiologyAgedRetrospective StudiesAged 80 and overKidneyCreatininebusiness.industryTroponin IRetrospective cohort studyCell BiologyMiddle AgedPrognosismedicine.diseasePulmonary embolismLogistic Modelsmedicine.anatomical_structureROC CurvechemistryEchocardiographyCreatinineAcute DiseaseMultivariate AnalysisPulmonary arteryCardiologyFemalePulmonary EmbolismbusinessExperimental Gerontology
researchProduct

Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A…

2016

Summary Objective In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as dia…

MaleCaptoprilDiabetic CardiomyopathiesMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologychemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineDiabetes mellitusRamiprilRetrospective StudieCardiovascular DiseaseMedicinePharmacology (medical)030212 general & internal medicineMyocardial infarctionDiabetic CardiomyopathieRandomized Controlled Trials as TopicAspirinLeft ventricular dysfunctionGeneral MedicineAcetyl salicylic acid; Acute myocardial infarction; Angiotensin-converting enzyme inhibitors; Diabetes mellitus; Left ventricular dysfunction; Ramipril; Zofenopril; Cardiology and Cardiovascular Medicine; Pharmacology (medical); PharmacologyMiddle AgedZofenoprilAcetyl salicylic acidCardiovascular DiseasesCardiologyPlatelet aggregation inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugHumanRamiprilmedicine.medical_specialtyDiabetes mellituSystoleAcute myocardial infarctionZofenopril03 medical and health sciencesDiabetes mellitusInternal medicineHumansAgedRetrospective StudiesPharmacologyAspirinbusiness.industryPlatelet Aggregation InhibitorAngiotensin-Converting Enzyme Inhibitormedicine.diseasechemistryAngiotensin-converting enzyme inhibitorbusinessMacePlatelet Aggregation Inhibitors
researchProduct

Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After A…

2017

Abstract: The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid. We now report CV outcomes during a 5-year follow-up of the patients of the SMILE-4 study. Three hundred eighty-six of the 518 patients completing the study (51.2%) could be tracked after the study end and 265 could be included in the analysis. During the 5.5 (±2.1) years of follow-up, the primary endpoint occurred in 27.8% of patients originall…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier Estimate030204 cardiovascular system & hematologyVentricular Function Leftchemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineRetrospective StudieRisk FactorsClinical endpointOdds Ratiozofenopril030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as Topicleft ventricular dysfunctionMortality ratePharmacology; Cardiology and Cardiovascular MedicineMiddle AgedZofenoprilHospitalizationTreatment OutcomeCardiologyOriginal ArticleDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineHumanmedicine.drugRamiprilmedicine.medical_specialtyLogistic ModelTime FactorSystoleacute myocardial infarctionramiprilDisease-Free SurvivalDrug Administration ScheduleFollow-Up Studie03 medical and health sciencesStatistical significanceInternal medicineEarly Medical InterventionmedicineHumansIntensive care medicineAgedRetrospective StudiesPharmacologyChi-Square DistributionAspirinbusiness.industryRisk FactorAngiotensin-Converting Enzyme InhibitorOdds ratioRecovery of Functionmedicine.diseaseConfidence intervalLogistic ModelschemistryClinical Trials Phase III as Topicbusinessacetyl salicylic acidFollow-Up StudiesJournal of Cardiovascular Pharmacology
researchProduct

Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acut…

2012

Background: Angiotensin-converting enzyme inhibitors (ACEIs) are largely employed for treating patients with left ventricular dysfunction (LVD), but their efficacy may be negatively affected by concomitant administration of acetylsalicylic acid (ASA), with some difference among the different compounds. Hypothesis: The interaction between ASA and the two ACEIs zofenopril and ramipril may result in a different impact on survival of cardiac patients, due to differences in the pharmacological properties of the two ACEIs. Methods: This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/d…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateVentricular Function Leftlaw.inventionchemistry.chemical_compoundVentricular Dysfunction LeftRandomized controlled trialRamiprillawRisk FactorsOdds RatioMyocardial infarctionProspective Studieseducation.field_of_studyEjection fractionGeneral MedicineMiddle AgedZofenoprilEuropeHospitalizationTreatment OutcomeCardiologyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugRamiprilmedicine.medical_specialtySystolePopulationClinical InvestigationsRisk AssessmentDouble-Blind MethodInternal medicinemedicineHumanseducationAgedHeart FailureChi-Square DistributionAspirinbusiness.industryStroke Volumeacetylsalicylic acidmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryLogistic ModelschemistryAngiotensin-converting enzyme inhibitorHeart failureMyocardial infarction complicationsZofenopril ramipril myocardial infarctionbusinessPlatelet Aggregation Inhibitors
researchProduct